A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

NCT00077870 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
237
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Genentech, Inc.